



# MOUD Treatment Performance Measures Implemented among Providers in Pennsylvania

University of Pittsburgh  
School of Pharmacy



Katie Wooten, MPH <sup>1,A</sup>, Dylan Pieper, MA <sup>1,A</sup>, Janice Pringle, PhD <sup>1,A</sup>

1. University of Pittsburgh School of Pharmacy Program Evaluation and Research Unit, A. Nothing to disclose

## INTRODUCTION


- Opioid use disorder (OUD) quality measures are recommended to systematically identify effective strategies for expanding access to quality medications for opioid use disorder (MOUD) treatment.<sup>1-3</sup>
- MOUD providers maintain patient treatment data; however, few develop or use standardized quality measures.<sup>3</sup>
- The Pennsylvania MOUD Expansion Project operationalized clinical quality guidelines and evidence-based research to create standardized MOUD treatment performance measures using electronic health record (EHR) data.
- The implemented MOUD treatment quality measures identified performance measure benchmarks among a cohort of participating MOUD providers.

## METHODS

- We recruited 25 practice sites across urban and rural Pennsylvania and requested EHR data-sharing and completion of a Data Use Agreement (DUA).
- We used a template of common EHR data fields specifying MOUD treatment measure components to implement data-sharing comprised of a limited dataset of patient-level MOUD treatment data. Measures included:
  1. % buprenorphine (versus naltrexone) prescriptions.
  2. % patient engagement in treatment the month following initiation by medication type.
  3. % patients retained at 90 and 180 days by medication type regardless of the time between prescriptions.
  4. Length of buprenorphine treatment based on initial and recurring episode of care without gaps in prescribing greater than 60 days.
- Results shown include n = 5,487 patients between January 2021-October 2022 from N=9 practice sites.

## RESULTS

- **95% of patients were prescribed buprenorphine compared to naltrexone**



The colored line represents the mean across site groups, by medication type.

### Buprenorphine (patient-level performance)

- **73%** of patients engaged the month after initiation of treatment
- **65%** of patients were retained at **90 days**
- **60%** of patients were retained at **180 days**

### Buprenorphine (practice-level performance)

- Treatment engagement after initiation ranged from **71% to 100%**
- 90-day retention ranged from **60% to 90%**
- 180-day retention ranged from **56% to 85%**

## TREATMENT LENGTH

Sites	A	B	C	D	E	F	G	H	I
% of N	67%	12%	6%	4%	3%	2%	2%	1%	0.4%
mean	256	273	455	220	424	157	338	348	343

Mean days (overall): 278

Median days [95% CI]: 139 [126, 154]

## CONCLUSION

- Developing widely used quality measures for the treatment of OUD is an important step toward improving access to quality MOUD treatment.
- Our project developed and then used standardized MOUD performance measure to compare patient engagement and retention across nine health systems in Pennsylvania, providing a basis for subsequent continuous quality improvement.
- Our combined site results were weighted toward the health system with the most patients (n = 3,920), a practice group with unique patient, provider, and system-level factors influencing treatment outcomes. Future reporting could be enhanced by comparing performance measure results by treatment model (e.g., primary care).

## REFERENCES

1. Johnson K, Hills H, Ma J, Brown CH, McGovern M. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality. *The American journal of drug and alcohol abuse*. 2021 Mar 4;47(2):220-8.
2. Martin SA, Chiodo LM, Wilson A. Retention in care as a quality measure for opioid use disorder. *Substance Abuse*. 2019 Oct 2;40(4):453-8.
3. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M. Developing an opioid use disorder treatment cascade: A review of quality measures. *Journal of substance abuse treatment*. 2018 Aug 1;91:57-68.

## ACKNOWLEDGEMENT

Research is supported by the Pennsylvania Department of Drug and Alcohol Programs (DDAP) under award # 418516 (PI: Janice Pringle, PhD).